An official website of the United States government

Compounds

Patent
US-2020002323-A1
Inventor

CUI HAIFENG (US)

REN FENG (CN)

SANG YINGXIA (CN)

ZHANG XIAOMIN (CN)

Assignee
GLAXOSMITHKLINE IP DEV LTD (GB)
Country
United States
Dates
  • Priority:
    2017/01/25
Description
This web page summarizes information in PubChem about patent US-2020002323-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed, please visit the PubChem patents help page.

1 Abstract

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

2 Full Text

3 Important Dates

3.1 Priority Date

2017/01/25

3.2 Filing Date

2018/01/23

3.3 Publication Date

2020/01/02

4 Inventor

CUI HAIFENG (US)

REN FENG (CN)

SANG YINGXIA (CN)

ZHANG XIAOMIN (CN)

5 Assignee

GLAXOSMITHKLINE IP DEV LTD (GB)

6 Country

United States

7 Linked Chemicals

7.1 PubChem Compounds

7.2 PubChem Substances

8 Linked Proteins

9 Linked Genes

10 Linked Taxonomies

11 Patent Family

12 Classification

12.1 IPC

C07D401/14 (inventive)

A61P25/16 (inventive)

C07D413/14 (inventive, first)

12.2 CPC

A61P25/16 (inventive)

C07D413/14 (inventive, first)

C07D401/14 (inventive)

13 Cited By

14 Similar Patents

15 Information Sources

  1. Google Patents
    LICENSE
    "Google Patents Research Data" by Google, based on data provided by IFI CLAIMS Patent Services and OntoChem, is licensed under a Creative Commons Attribution 4.0 International License.
    https://creativecommons.org/licenses/by/4.0/legalcode
  2. PubChem
CONTENTS